GCs are currently the most effective anti-inflammatory therapy for COPD; however, it has been confirmed that posttranslational modifications of glucocorticoid receptors (GRs), as well as decreased expression and activity of HDAC2, lead to the GCs resistance in patients with COPD [29]. Here, NR3C1 is linked to chronic obstructive pulmonary disease.